

MAP Number: 2025-DK-CSO-00013

ODS/One Key ID Number: [Click or tap here to enter text.](#)

Vendor Number: [Click or tap here to enter text.](#)

SPONSORSHIP AGREEMENT

Parties:

This Sponsorship Agreement ("Agreement") is between

AbbVie A/S,

CVR/VAT no: 34 46 28 28

Titangade 11, DK-2200 Copenhagen N, Denmark

("AbbVie")

and

Institution/ Health Care Organization (from now on "Institution")	LyLe - Patientforeningen for Lymfekræft, Leukæmi og MDS.
Address	Banetoften 26, 4700 Naestved
Institution's Organizational number:	CVR-nummer: 31 30 68 33
If applicable: Third Party appointed by the Institution to organize the activity:	-
Organization's number for the Third Party appointed by the Institution:	-
Payment of the sponsorship shall be made to the appointed Third Party	No.

AbbVie and the Institution are collectively named the "Parties".

1. Sponsorship:

AbbVie hereby agrees to fund the scientific part of this Institutions' activity with the following amount:	26.687,50 DKK
Date of the activity (format DD-MMM-YYYY)	25-04-2025 onwards
City of the activity/Online	Naestved
Venue/Virtual	www.lyle.dk
Name of the activity	Awareness pamphlet on what it means to enrol in a clinical trial

- The sponsorship is based on the institution's proposed detailed budget and/or breakdown of costs for the activity.
- The sponsorship can only cover direct expenses actually incurred. This means, e.g. that mileage compensation according to state tariffs for external speakers' travel in own car cannot be covered.

2. Commercial Benefits:

In return for the sponsorship AbbVie shall receive the following items as a counter performance at reasonable market value, (e.g. a booth, registration of participants, logo, product information in the agenda, logos in the materials, symposia):

- Pamphlet.

MAP Number: 2025-DK-CSO-00013

ODS/One Key ID Number: [Click or tap here to enter text.](#)

Vendor Number: [Click or tap here to enter text.](#)

3. Obligations

By accepting this Sponsorship, the Institution commits to:

- a. Provide AbbVie proof of performance of the sponsored activities/items.
- b. Comply with the meal limits according to the local Pharma Code.
- c. Not using AbbVie sponsorship for activities that involve entertainment, social activities, leisure, day-to-day business costs, or activities that do not comply with the requirements of the local Pharma Code.
- d. Ensure that the primary purpose of the event is scientific or medical and educational in its nature.
- e. Ensuring that the event will be held at a place that is appropriate for the primary purpose of the meeting complying with the requirements of the local Pharma Code.
- f. Ensure that the sponsorship only covers direct expenses actually incurred, as explained under section 1 above.

4. Payment

AbbVie shall pay the sponsorship within 45 days from receipt of a correct invoice.

5. Transparency and Accountability

There should be full transparency and disclosure of this Agreement according to the Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations ("the EFPIA Disclosure Code").

The Institution shall transparently declare that AbbVie has sponsored the activity.

6. Compliance with Laws

This Agreement is not an inducement to purchase, prescribe or recommend AbbVie products.

The Institution represents and warrants that it is in compliance with, and undertakes that in its performance of its obligations under this Agreement it shall continue to comply with, all applicable laws and regulations, including applicable anti-corruption laws, data privacy laws and the ethical rules of the pharmaceutical industry. The Assignee warrants that it, to the best of its knowledge, does not and will not engage any person or entity to perform services under this agreement who was convicted for any criminal offense, e.g. payment of illegal gratuities, fraud, false statement, blackmail, falsification or destruction of records.

7. Term and Termination

This agreement shall become effective on the date of signature by both parties. The agreement shall be valid until the activity has been carried out and all obligations under the agreement have been fulfilled by the Parties, after which the agreement will automatically expire.

Either party may terminate this Agreement prematurely at any time by written notice to the other party. If the Agreement is terminated prematurely for any reason, the sponsorship shall not be paid out. If payment has already been made, the Institution shall repay AbbVie as soon as possible.

8. Entire Agreement

MAP Number: 2025-DK-CSO-00013

ODS/One Key ID Number: [Click or tap here to enter text.](#)

Vendor Number: [Click or tap here to enter text.](#)

This Agreement constitutes the Parties' entire agreement on all issues which the Agreement relates to. Modifications of or additions to this Agreement need to be valid in writing and signed by authorized representatives of both Parties.

9. Miscellaneous

Danish law shall be applicable to this Agreement.

Signatures:

Date

For AbbVie A/S

Date

Signed for Lyle

thea larsen

[thea larsen \(08-Apr-2025 15:35 GMT+2\)](#)

Signature

Thea Larsen, Country Lead, Denmark

Rita O. Christensen

[Rita O. Christensen \(09-Apr-2025 11:25 GMT+2\)](#)

Signature

Rita O. Christiansen, Formand Lyle